Phase Ia/Ib multicenter investigator initiated trial of Mogamulizumab for advanced or recurrent cancer
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Gastric cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer
- Focus Adverse reactions; Pharmacokinetics
- 18 Oct 2017 Results (n=6) assessing response against chemotherapy before and after mogamulizumab treatment in 6 advanced lung cancer patients who were enrolled in the clinical trial, were presented at the 18th World Conference on Lung Cancer.
- 20 Feb 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2016 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.